Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 4 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 1

Conditions

Refractory Differentiated Thyroid Gland Carcinoma 1Differentiated Thyroid Cancer (DTC) 1

Interventions

pembrolizumab 81Carboplatin 76Magnetic Resonance Spectroscopy 73Specimen Handling 69Cisplatin 62Paclitaxel 55Gemcitabine 46Fluorouracil 37Dexamethasone 37Radiation 36Docetaxel 36Cyclophosphamide 36Radiotherapy 35Pemetrexed 35Doxorubicin 35Oxaliplatin 33Leucovorin 33Bevacizumab 31Capecitabine 28Vincristine 27durvalumab 26Etoposide 24Rituximab 23Taxes 22Irinotecan 22Nivolumab 21Letrozole 21Prednisone 20Biopsy 20Platinum 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × dabrafenib × 30 days × Clear all
NCT04940052 2026-05-22

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

NCT06475989 2026-05-15

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Eastern Cooperative Oncology Group

Phase 3 Recruiting
264 enrolled
Head & Neck

Refractory Differentiated Thyroid Gland Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡